Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated:  1/3/2017
Greenville Health System NCORP
mi
from
Greenville, SC
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated: 1/3/2017
Greenville Health System NCORP
mi
from
Greenville, SC
Click here to add this to my saved trials
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated:  1/3/2017
Wisconsin NCORP
mi
from
Marshfield, WI
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated: 1/3/2017
Wisconsin NCORP
mi
from
Marshfield, WI
Click here to add this to my saved trials
Patient Perception of Mammogram Guidelines
Patient Perception of Mammogram Guidelines
Status: Enrolling
Updated:  1/4/2017
UMassMemorial Medical Group- Auburn Gyn
mi
from
Auburn, MA
Patient Perception of Mammogram Guidelines
Patient Perception of Mammogram Guidelines
Status: Enrolling
Updated: 1/4/2017
UMassMemorial Medical Group- Auburn Gyn
mi
from
Auburn, MA
Click here to add this to my saved trials
Patient Perception of Mammogram Guidelines
Patient Perception of Mammogram Guidelines
Status: Enrolling
Updated:  1/4/2017
Shrewsbury Ob-Gyn
mi
from
Shrewsbury, MA
Patient Perception of Mammogram Guidelines
Patient Perception of Mammogram Guidelines
Status: Enrolling
Updated: 1/4/2017
Shrewsbury Ob-Gyn
mi
from
Shrewsbury, MA
Click here to add this to my saved trials
Patient Perception of Mammogram Guidelines
Patient Perception of Mammogram Guidelines
Status: Enrolling
Updated:  1/4/2017
UMassMemorial Medical Group- OB-GYN
mi
from
Shrewsbury, MA
Patient Perception of Mammogram Guidelines
Patient Perception of Mammogram Guidelines
Status: Enrolling
Updated: 1/4/2017
UMassMemorial Medical Group- OB-GYN
mi
from
Shrewsbury, MA
Click here to add this to my saved trials
Patient Perception of Mammogram Guidelines
Patient Perception of Mammogram Guidelines
Status: Enrolling
Updated:  1/4/2017
Women's Health of Central Mass
mi
from
Worcester, MA
Patient Perception of Mammogram Guidelines
Patient Perception of Mammogram Guidelines
Status: Enrolling
Updated: 1/4/2017
Women's Health of Central Mass
mi
from
Worcester, MA
Click here to add this to my saved trials
Creation of the BioBank, Early Detection and Discovery Biomarkers
Creation of the BioBank,To Establish a Multidisciplinary Research Structure That Facilitates Projects That Bridge Specialties That Normally May or May Not Interact.
Status: Enrolling
Updated:  1/5/2017
William Beaumont Hospitals
mi
from
Royal Oak, MI
Creation of the BioBank, Early Detection and Discovery Biomarkers
Creation of the BioBank,To Establish a Multidisciplinary Research Structure That Facilitates Projects That Bridge Specialties That Normally May or May Not Interact.
Status: Enrolling
Updated: 1/5/2017
William Beaumont Hospitals
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
Combined Fulvestrant and Anastrozole as Neo-adjuvant Endocrine Therapy in Postmenopausal Women With Hormone Receptor Positive Invasive Breast Cancer
Status: Enrolling
Updated:  1/5/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
Combined Fulvestrant and Anastrozole as Neo-adjuvant Endocrine Therapy in Postmenopausal Women With Hormone Receptor Positive Invasive Breast Cancer
Status: Enrolling
Updated: 1/5/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Internet-based System for Cancer Patients to Self-report Toxicity
Pilot Study of STAR, an Internet-based System for Cancer Patients to Self-report Toxicity Symptoms, Performance Status, and Quality of Life
Status: Enrolling
Updated:  1/9/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Internet-based System for Cancer Patients to Self-report Toxicity
Pilot Study of STAR, an Internet-based System for Cancer Patients to Self-report Toxicity Symptoms, Performance Status, and Quality of Life
Status: Enrolling
Updated: 1/9/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
TOBI to Monitor Response to Neoadjuvant Therapy in Breast Cancer
Functional Metabolic Near-infrared Tomographic Optical Breast Imaging (TOBI) to Monitor Response to Neoadjuvant Therapy in Breast Cancer
Status: Enrolling
Updated:  1/9/2017
Massachusetts General Hospital
mi
from
Boston, MA
TOBI to Monitor Response to Neoadjuvant Therapy in Breast Cancer
Functional Metabolic Near-infrared Tomographic Optical Breast Imaging (TOBI) to Monitor Response to Neoadjuvant Therapy in Breast Cancer
Status: Enrolling
Updated: 1/9/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
UCSF
mi
from
San Francisco, CA
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
UCSF
mi
from
San Francisco, CA
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
Georgetown - Lombardi Cancer Center
mi
from
Washington,
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
Georgetown - Lombardi Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
Johns Hopkins University Medical Center
mi
from
Baltimore, MD
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
Johns Hopkins University Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
Massachusetts General Hospital
mi
from
Boston, MA
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
North Shore Medical Center
mi
from
Peabody, MA
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
North Shore Medical Center
mi
from
Peabody, MA
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Gene Therapy in Treating Women With Metastatic Breast Cancer
Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patents With Metastatic Breast Cancer
Status: Enrolling
Updated:  1/10/2017
Icahn Medical Center at Mount Sinai
mi
from
New York, NY
Gene Therapy in Treating Women With Metastatic Breast Cancer
Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patents With Metastatic Breast Cancer
Status: Enrolling
Updated: 1/10/2017
Icahn Medical Center at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Testing New Method of Analyzing MR Images
Imaging Protocol Design for Anti-Angiogenesis Tracking With MRI
Status: Enrolling
Updated:  1/11/2017
Methodist Hospital
mi
from
Indianapolis, IN
Testing New Method of Analyzing MR Images
Imaging Protocol Design for Anti-Angiogenesis Tracking With MRI
Status: Enrolling
Updated: 1/11/2017
Methodist Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
Comprehensive Cancer Centers of the Desert
mi
from
Palm Springs, CA
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
Comprehensive Cancer Centers of the Desert
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
Loyola University Medical Center
mi
from
Maywood, IL
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
Arthur G. James Cancer Hospital - Ohio State University
mi
from
Columbus, OH
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
Arthur G. James Cancer Hospital - Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
U.S. Oncology Research, Inc.
mi
from
Dallas, TX
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
U.S. Oncology Research, Inc.
mi
from
Dallas, TX
Click here to add this to my saved trials
Comparison of Preoperative ABUS and MRI in Newly Diagnosed Breast Cancer Patients
Comparison of Preoperative Automated Breast Ultrasound (ABUS) and Magnetic Resonance Imaging (MRI) in Newly Diagnosed Breast Cancer Patients
Status: Enrolling
Updated:  1/18/2017
University of Kansas Cancer Center
mi
from
Westwood, KA
Comparison of Preoperative ABUS and MRI in Newly Diagnosed Breast Cancer Patients
Comparison of Preoperative Automated Breast Ultrasound (ABUS) and Magnetic Resonance Imaging (MRI) in Newly Diagnosed Breast Cancer Patients
Status: Enrolling
Updated: 1/18/2017
University of Kansas Cancer Center
mi
from
Westwood, KA
Click here to add this to my saved trials
Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer
Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer
Status: Enrolling
Updated:  1/18/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer
Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer
Status: Enrolling
Updated: 1/18/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer
Evaluation of a Yoga-Based Cancer Rehabilitation Program
Status: Enrolling
Updated:  1/23/2017
Albert Einstein College of Medicine
mi
from
Bronx, NY
Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer
Evaluation of a Yoga-Based Cancer Rehabilitation Program
Status: Enrolling
Updated: 1/23/2017
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Image-guided Breast Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO)
A Pilot Study to Evaluate Image-guided Breast Conserving Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO)
Status: Enrolling
Updated:  1/23/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Image-guided Breast Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO)
A Pilot Study to Evaluate Image-guided Breast Conserving Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO)
Status: Enrolling
Updated: 1/23/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Image-guided Breast Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO)
A Pilot Study to Evaluate Image-guided Breast Conserving Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO)
Status: Enrolling
Updated:  1/23/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Image-guided Breast Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO)
A Pilot Study to Evaluate Image-guided Breast Conserving Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO)
Status: Enrolling
Updated: 1/23/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Identification of a Screening Tool and Treatment of Lymphedema Secondary to the Management of Breast Cancer Study
Identification of a Screening Tool and Treatment of Lymphedema Secondary to the Management of Breast Cancer Study
Status: Enrolling
Updated:  1/23/2017
Avon Breasts Center, Johns Hopkins Medical Institutions
mi
from
Baltimore, MD
Identification of a Screening Tool and Treatment of Lymphedema Secondary to the Management of Breast Cancer Study
Identification of a Screening Tool and Treatment of Lymphedema Secondary to the Management of Breast Cancer Study
Status: Enrolling
Updated: 1/23/2017
Avon Breasts Center, Johns Hopkins Medical Institutions
mi
from
Baltimore, MD
Click here to add this to my saved trials
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated:  1/27/2017
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated: 1/27/2017
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated:  1/27/2017
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated: 1/27/2017
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Click here to add this to my saved trials
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated:  1/27/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated: 1/27/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated:  1/27/2017
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated: 1/27/2017
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated:  1/27/2017
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated: 1/27/2017
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated:  1/27/2017
Memorial Sloan Kettering West Harrison
mi
from
West Harrison, NY
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated: 1/27/2017
Memorial Sloan Kettering West Harrison
mi
from
West Harrison, NY
Click here to add this to my saved trials
DAMES: Daughters And MothErS Against Breast Cancer
DAMES: Daughters And MothErS Against Breast Cancer
Status: Enrolling
Updated:  2/1/2017
Duke Univ Med Ctr
mi
from
Durham, NC
DAMES: Daughters And MothErS Against Breast Cancer
DAMES: Daughters And MothErS Against Breast Cancer
Status: Enrolling
Updated: 2/1/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
DAMES: Daughters And MothErS Against Breast Cancer
DAMES: Daughters And MothErS Against Breast Cancer
Status: Enrolling
Updated:  2/1/2017
UT MD Anderson Cancer Center
mi
from
Houston, TX
DAMES: Daughters And MothErS Against Breast Cancer
DAMES: Daughters And MothErS Against Breast Cancer
Status: Enrolling
Updated: 2/1/2017
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Little Rock, AR
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
mi
from
Deer Park, CA
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
mi
from
Deer Park, CA
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Greenbrae, CA
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Greenbrae, CA
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
La Jolla, CA
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials